Aralez Pharmaceuticals Inc (ARLZ) Price Target Cut to $5.50 by Analysts at Chardan Capital
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) had its price target lowered by Chardan Capital from $10.00 to $5.50 in a research note published on Wednesday. The brokerage currently has a buy rating on the stock.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 2.36 on Wednesday. Aralez Pharmaceuticals has a 52 week low of $2.05 and a 52 week high of $6.80. The company’s market cap is $154.58 million. The company has a 50-day moving average price of $3.88 and a 200 day moving average price of $4.58.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Monday, March 13th. The company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The business earned $20 million during the quarter, compared to analysts’ expectations of $21.86 million. During the same period last year, the business earned ($0.40) earnings per share. The company’s revenue for the quarter was up 233.3% compared to the same quarter last year. On average, equities research analysts forecast that Aralez Pharmaceuticals will post ($1.07) EPS for the current fiscal year.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/aralez-pharmaceuticals-inc-arlz-price-target-cut-to-5-50-by-analysts-at-chardan-capital.html
Your IP Address:
In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch bought 45,000 shares of the firm’s stock in a transaction on Wednesday, March 15th. The shares were acquired at an average cost of $2.27 per share, with a total value of $102,150.00. Following the purchase, the director now directly owns 149,109 shares of the company’s stock, valued at approximately $338,477.43. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Adrian Adams bought 500,000 shares of the firm’s stock in a transaction on Wednesday, March 15th. The stock was acquired at an average cost of $2.46 per share, for a total transaction of $1,230,000.00. Following the completion of the purchase, the chief executive officer now directly owns 3,569,230 shares in the company, valued at $8,780,305.80. The disclosure for this purchase can be found here. Insiders acquired a total of 549,750 shares of company stock worth $1,342,173 over the last three months. Corporate insiders own 6.77% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARLZ. Dynamic Technology Lab Private Ltd acquired a new position in Aralez Pharmaceuticals during the fourth quarter worth $103,000. Shufro Rose & Co. LLC raised its position in Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock worth $104,000 after buying an additional 5,000 shares during the period. J. Goldman & Co LP acquired a new position in Aralez Pharmaceuticals during the fourth quarter worth $198,000. Nwam LLC acquired a new position in Aralez Pharmaceuticals during the third quarter worth $228,000. Finally, FNY Managed Accounts LLC raised its position in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock worth $286,000 after buying an additional 7,000 shares during the period. 44.01% of the stock is currently owned by institutional investors and hedge funds.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.